ISRG slips after earnings as Street holds firm on the bull case

Intuitive Surgical heads into the final stretch of October nursing a 4.5% weekly loss, even as the analyst community emerged from Q3 results mostly constructive on the robotic surgery franchise.

The Street's reaction to the October 20 print was broadly positive in direction but mixed in conviction. JPMorgan's Robbie Marcus raised his target to $475 from $450, keeping Overweight, while Barclays and Leerink Partners also lifted targets, to $500 and $503 respectively. Baird was the most bullish mover, pushing its Outperform target to $550 from $513. Not everyone followed. Evercore ISI trimmed to $385 from $400, maintaining its In-Line rating, RBC cut from $575 to $550, and Mizuho shaved its Neutral target to $400. The mean target across the group is $483, roughly 12% above the current price of $432. That gap suggests the Street sees more value here than the tape is offering this week, though the divergence in target moves reflects genuine disagreement about near-term momentum rather than a clean bull signal.

The bull case rests on the installed base. With more than 11,000 da Vinci systems deployed and over 20 million procedures completed, the platform's barriers to entry are the core argument. Q3 revenue hit $3.05 billion, the company placed 546 new da Vinci systems, and U.S. procedure growth ran near 10%. Bulls point to the DV5 upgrade cycle, rising ambulatory surgery centre adoption, and expanding international demand as the next legs of the story. Bears focus on the deceleration: U.S. procedure growth came in at 10% in Q3, down from 12% in Q2 and 14% in Q1, and management only narrowed full-year guidance to 14 to 15% rather than raising it. China adds a specific pressure point, with a policy-driven charge code change set to weigh on revenue per procedure from November, against a backdrop where China already runs roughly 20% below the global blended average per-procedure rate. The EV/EBITDA multiple sits at 25.2x, the PE at 36.6x, both meaningful premiums that leave little room for volume disappointments. Factor scores are mixed: analyst recommendation breadth ranks in the 94th percentile, and forward EPS growth momentum sits in the 83rd percentile over 30 days, but the earnings surprise percentile is only 31, and value metrics are firmly in the lower half of the universe.

Short positioning is not part of this week's story. Short interest is 2.1% of the free float, barely changed over the week, and the borrow market is loose by almost any measure. Availability is running at over 7,000%, meaning shares to borrow vastly outnumber shares already borrowed. Cost to borrow has ticked up to 0.57%, roughly double its level two weeks ago, but even at that rate it remains trivially cheap to hold a short. The ORTEX short score of 32.9 is at the low end, consistent with a stock where short sellers are present but not pressing. Options positioning is equally unremarkable: the put/call ratio of 0.81 sits almost exactly in line with its 20-day average of 0.81, a z-score of just 0.23. Neither the borrow market nor the options market is flagging elevated bearish pressure after the print.

One alt-data point worth noting: Wikipedia views of the Intuitive Surgical page spiked to a z-score of 2.7 relative to the prior 90 days as of October 21, the day after Q3 results. That is a retail attention signal rather than a revenue indicator, and no alt-data dataset for ISRG has been measured to lead its reported figures.

The insider register is routine rather than notable. Recent sales from the EVP of Manufacturing and the VP Corporate Controller were all executed under pre-arranged 10b5-1 plans, small in size and low in significance. Institutional ownership is stable, with BlackRock at 8.7% and Vanguard at 7.3% as the two largest holders; both added marginally in the September quarter. The next earnings event is not until January 19, 2027, giving the market 80 days to form a view on whether the U.S. procedure deceleration stabilises or extends into Q4.

The key question for the weeks ahead is whether the China pricing change in November produces a visible drag on per-procedure economics in the Q4 print, and whether U.S. volume can hold near the 10% level or continues the step-down pattern seen across the first three quarters of the year.